Advertisement

Transfusion Medicine

  • Emily K. Storch
  • Brian S. Custer
  • Jay E. Menitove
  • Paul D. MintzEmail author
Chapter

Abstract

The field of blood banking and transfusion medicine incorporates elements of blood donation and collection, blood component manufacture, pretransfusion testing including serology and molecular methods, blood transfusion therapy, and clinical consultation. Blood and blood components are regulated by the FDA both as biological products and as drugs. Blood collection primarily occurs in blood centers, whereas most transfusions are performed by hospital transfusion services. The primary blood components used in transfusion include red blood cells, platelets, plasma, and cryoprecipitate. Less frequently, whole blood is transfused, particularly in military situations. Further processing of blood and blood components may include leukocyte reduction, irradiation, washing, volume reduction, and CMV-serology testing. Indications for transfusion vary based on the clinical situation and individual patient characteristics. Significant adverse events of transfusion can be categorized into immediate reactions (e.g., acute hemolytic transfusion reactions (AHTR)) and delayed reactions (e.g., delayed hemolytic transfusion reactions (DHTR)). Transfusion-transmitted infection from viruses, bacteria, parasites, or other pathogens is another significant risk of blood transfusion. Measures used to mitigate the risk of transfusion-transmitted infection include donor screening procedures and testing of the blood supply for pathogens with various methods, as well as new technologies such as pathogen reduction.

As the practice of transfusion medicine continues to evolve, the importance of systemic blood transfusion surveillance, known as hemovigilance, has gained increasing recognition. Hemovigilance encompasses the spectrum of donor through recipient transfusion processes, in order to monitor, track, and respond to both infectious and noninfectious risks from blood transfusion. Risk-based decision-making is another initiative that has arisen in recent years, referring to the development of a framework to prioritize decisions regarding blood safety balanced by availability of the blood supply. Finally, health economics and cost-effectiveness are important considerations necessary to inform risk-based decision-making and ensure preservation of a safe and available blood supply.

Keywords

Blood banking Transfusion medicine Blood component Transfusion-transmitted infection Adverse reactions to transfusion 

References

  1. 1.
    Tasaki T, Ohto H. Nineteen years of experience with autotransfusion for elective surgery in children: more troublesome than we expected. Transfusion. 2007;47(8):1503–9.PubMedGoogle Scholar
  2. 2.
    Saa P, Proctor M, Foster G, et al. Investigational testing for Zika virus among U.S. blood donors. N Engl J Med. 2018;378(19):1778–88.PubMedGoogle Scholar
  3. 3.
    Chung KW, Basavaraju SV, Mu Y, et al. Declining blood collection and utilization in the United States. Transfusion. 2016;56(9):2184–92.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Sadana D, Pratzer A, Scher LJ, et al. Promoting high-value practice by reducing unnecessary transfusions with a patient blood management program. JAMA Intern Med. 2018;178(1):116–22.PubMedGoogle Scholar
  5. 5.
    Spinella PC, Pidcoke HF, Strandenes G, et al. Whole blood for hemostatic resuscitation of major bleeding. Transfusion. 2016;56(Suppl 2):S190–202.PubMedGoogle Scholar
  6. 6.
    Robertson LB. The transfusion of whole blood: a suggestion for its more frequent employment in war surgery. Br Med J. 1916;2(2897):38–40.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Spinella PC, Perkins JG, Grathwohl KW, Beekley AC, Holcomb JB. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma. 2009;66(4 Suppl):S69–76.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Spinella PC, Doctor A. Role of transfused red blood cells for shock and coagulopathy within remote damage control resuscitation. Shock. 2014;41(Suppl 1):30–4.PubMedGoogle Scholar
  9. 9.
    Butler FK, Holcomb JB, Schreiber MA, et al. Fluid resuscitation for hemorrhagic shock in tactical combat casualty care: TCCC guidelines change 14-01 – 2 June 2014. J Spec Oper Med. 2014;14(3):13–38.PubMedGoogle Scholar
  10. 10.
    Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United States blood collection and transfusion: results from the 2013 AABB blood collection, utilization, and patient blood management survey. Transfusion. 2016;56(9):2173–83.PubMedGoogle Scholar
  11. 11.
    Gunter P. Practice guidelines for blood component therapy. Anesthesiology. 1996;85(5):1219–20.PubMedGoogle Scholar
  12. 12.
    Kwok CS, Sherwood MW, Watson SM, et al. Blood transfusion after percutaneous coronary intervention and risk of subsequent adverse outcomes: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2015;8(3):436–46.PubMedGoogle Scholar
  13. 13.
    Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med. 2009;37(12):3124–57.PubMedGoogle Scholar
  14. 14.
    Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion. 2010;50(10):2117–24.PubMedGoogle Scholar
  15. 15.
    Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial. JAMA. 2015;314(23):2514–23.PubMedGoogle Scholar
  16. 16.
    Fergusson DA, Hebert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308(14):1443–51.PubMedGoogle Scholar
  17. 17.
    Fernandes da Cunha DH, Nunes Dos Santos AM, Kopelman BI, et al. Transfusions of CPDA-1 red blood cells stored for up to 28 days decrease donor exposures in very low-birth-weight premature infants. Transfus Med. 2005;15(6):467–73.PubMedGoogle Scholar
  18. 18.
    Heddle NM, Cook RJ, Arnold DM, et al. Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016;375(20):1937–45.PubMedGoogle Scholar
  19. 19.
    Lacroix J, Hebert PC, Fergusson DA, et al. Age of transfused blood in critically ill adults. N Engl J Med. 2015;372(15):1410–8.PubMedGoogle Scholar
  20. 20.
    Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015;372(15):1419–29.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Cooper DJ, McQuilten ZK, Nichol A, et al. Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377(19):1858–67.PubMedGoogle Scholar
  22. 22.
    Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–35.PubMedGoogle Scholar
  23. 23.
    Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373–80.PubMedGoogle Scholar
  24. 24.
    Backholer L, Green L, Huish S, et al. A paired comparison of thawed and liquid plasma. Transfusion. 2017;57(4):881–9.PubMedGoogle Scholar
  25. 25.
    Roback JD, Caldwell S, Carson J, et al. Evidence-based practice guidelines for plasma transfusion. Transfusion. 2010;50(6):1227–39.PubMedGoogle Scholar
  26. 26.
    Green L, Bolton-Maggs P, Beattie C, et al. British society of Haematology guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. Br J Haematol. 2018;181(1):54–67.PubMedGoogle Scholar
  27. 27.
    Anderson I, Cifu AS. Management of bleeding in patients taking oral anticoagulants. JAMA. 2018;319(19):2032–3.PubMedGoogle Scholar
  28. 28.
    Curry N, Rourke C, Davenport R, et al. Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. Br J Anaesth. 2015;115(1):76–83.PubMedGoogle Scholar
  29. 29.
    O'Brien KL, Uhl L. How do we manage blood product support in the massively hemorrhaging obstetric patient? Transfusion. 2016;56(9):2165–71.PubMedGoogle Scholar
  30. 30.
    Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth. 2014;113(6):922–34.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Yang L, Stanworth S, Baglin T. Cryoprecipitate: an outmoded treatment? Transfus Med. 2012;22(5):315–20.PubMedGoogle Scholar
  32. 32.
    Nascimento B, Callum J, Tien H, et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. Br J Anaesth. 2016;117(6):775–82.PubMedGoogle Scholar
  33. 33.
    O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11–28.PubMedGoogle Scholar
  34. 34.
    Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–13.PubMedGoogle Scholar
  35. 35.
    Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283–99.PubMedGoogle Scholar
  36. 36.
    Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470–6.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126(18):2153–61.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Valentini CG, Farina F, Pagano L, Teofili L. Granulocyte transfusions: a critical reappraisal. Biol Blood Marrow Transplant. 2017;23(12):2034–41.PubMedGoogle Scholar
  39. 39.
    Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598–603.PubMedGoogle Scholar
  40. 40.
    Aabb CTMC, Heddle NM, Boeckh M, et al. AABB Committee report: reducing transfusion-transmitted cytomegalovirus infections. Transfusion. 2016;56(6 Pt 2):1581–7.Google Scholar
  41. 41.
    Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):58S–69S.PubMedGoogle Scholar
  42. 42.
    Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Canadian Orthopedic Perioperative Erythropoietin Study Group. Lancet. 1993;341(8855):1227–1232.Google Scholar
  43. 43.
    Kapadia BH, Banerjee S, Issa K, McElroy MJ, Harwin SF, Mont MA. Preoperative blood management strategies for total knee arthroplasty. J Knee Surg. 2013;26(6):373–7.PubMedGoogle Scholar
  44. 44.
    Enko D, Wallner F, von Goedecke A, Hirschmugl C, Auersperg V, Halwachs-Baumann G. The impact of an algorithm-guided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients. Anemia. 2013;2013:641876.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Goodnough LT, Maniatis A, Earnshaw P, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106(1):13–22.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160S–98S.Google Scholar
  47. 47.
    Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116(5):879–90.PubMedPubMedCentralGoogle Scholar
  48. 48.
    collaborators C-t, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32.Google Scholar
  49. 49.
    Pitta M, Zawadsky M, Verstraete R, Rubinstein A. Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series. Transfusion. 2016;56(2):466–71.PubMedGoogle Scholar
  50. 50.
    Collaborators WT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16.Google Scholar
  51. 51.
    Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN trial (world maternal Antifibrinolytic trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010;11:40.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg. 2012;147(2):113–9.PubMedGoogle Scholar
  53. 53.
    Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015;6:CD007872.  https://doi.org/10.1002/14651858.CD007872.pub3.
  54. 54.
    Styron JF, et al. Relative efficacy of tranexamic acid and preoperative anemia treatment for reducing transfusions in total joint arthroplasty. Transfusion. 2017;57(3):622–9.  https://doi.org/10.1111/trf.13955. Epub 2016.CrossRefPubMedGoogle Scholar
  55. 55.
    Personal communication, Giles Delage, Hema-Quebec, 2017.Google Scholar
  56. 56.
    Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–82.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Hunt H, et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev. 2015;(2):CD010438.  https://doi.org/10.1002/14651858.CD010438.pub2.
  58. 58.
    Butwick AJ, Goodnough LT. Transfusion and coagulation management in major obstetric hemorrhage. Curr Opin Anaesthesiol. 2015;28(3):275–84.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Simpson E, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012;(3):CD005011.  https://doi.org/10.1002/14651858.CD005011.pub4.
  60. 60.
    Liumbruno GM, D'Alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus. 2010;8(1):8–16.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion. 2000;40(12):1528–40.PubMedGoogle Scholar
  62. 62.
    Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617–21.PubMedGoogle Scholar
  63. 63.
    Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825–36.PubMedGoogle Scholar
  64. 64.
    Harvey AR, Basavaraju SV, Chung KW, Kuehnert MJ. Transfusion-related adverse reactions reported to the national healthcare safety network hemovigilance module, United States, 2010 to 2012. Transfusion. 2015;55(4):709–18.PubMedGoogle Scholar
  65. 65.
    Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 1999;39(3):231–8.PubMedGoogle Scholar
  66. 66.
    Savage WJ, Tobian AA, Savage JH, Wood RA, Schroeder JT, Ness PM. Scratching the surface of allergic transfusion reactions. Transfusion. 2013;53(6):1361–71.PubMedGoogle Scholar
  67. 67.
    Tobian AA, King KE, Ness PM. Prevention of febrile nonhemolytic and allergic transfusion reactions with pretransfusion medication: is this evidence-based medicine? Transfusion. 2008;48(11):2274–6.PubMedGoogle Scholar
  68. 68.
    Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008;48(11):2285–91.PubMedGoogle Scholar
  69. 69.
    Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev. 2007;21(1):1–12.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2004;44(1):16–24.PubMedGoogle Scholar
  71. 71.
    Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774–89.PubMedGoogle Scholar
  72. 72.
    Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573–7.PubMedGoogle Scholar
  73. 73.
    Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg. 2009;108(3):770–6.PubMedGoogle Scholar
  74. 74.
    Roubinian NH, et al. Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm. Vox Sang. 2017;112(1):56–63.  https://doi.org/10.1111/vox.12466. Epub 2016.CrossRefPubMedGoogle Scholar
  75. 75.
    Vamvakas EC, Pineda AA, Reisner R, Santrach PJ, Moore SB. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion. 1995;35(1):26–32.PubMedGoogle Scholar
  76. 76.
    Whitaker B, Hinkins S. The 2011 national blood collection and utilization survey report. n.d. https://www.hhs.gov/sites/default/files/ash/bloodsafety/2011-nbcus.pdf.
  77. 77.
    Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood. 2015;126(3):406–14.PubMedGoogle Scholar
  78. 78.
    Bahar B, Tormey CA. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation: the past, present, and future. Arch Pathol Lab Med. 2018;142(5):662–7.PubMedGoogle Scholar
  79. 79.
    Bolton-Maggs PH. Transfusion safety in 2012: main messages from the SHOT annual report for 2012. Transfus Med. 2013;23(4):217–8.PubMedGoogle Scholar
  80. 80.
    Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion. 2007;47(8):1455–67.PubMedGoogle Scholar
  81. 81.
    Remy KE, Hall MW, Cholette J, et al. Mechanisms of red blood cell transfusion-related immunomodulation. Transfusion. 2018;58(3):804–15.PubMedGoogle Scholar
  82. 82.
    Girard-Pierce KR, Stowell SR, Smith NH, et al. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood. 2013;122(10):1793–801.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Patel SR, Zimring JC. Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens. Transfus Med Rev. 2013;27(4):241–8.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Smith NH, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood. 2012;119(6):1566–9.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl 2):1S–29S.PubMedGoogle Scholar
  86. 86.
    Ammann AJ, Cowan MJ, Wara DW, et al. Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet. 1983;1(8331):956–8.PubMedGoogle Scholar
  87. 87.
    Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med. 1984;310(2):69–75.PubMedGoogle Scholar
  88. 88.
    Peterman TA, Jaffe HW, Feorino PM, et al. Transfusion-associated acquired immunodeficiency syndrome in the United States. JAMA. 1985;254(20):2913–7.PubMedGoogle Scholar
  89. 89.
    Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion. 1991;31(1):4–11.PubMedGoogle Scholar
  90. 90.
    Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50(7):1495–504.PubMedGoogle Scholar
  91. 91.
    Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion. 2009;49(11):2454–89.PubMedGoogle Scholar
  92. 92.
    Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion. 2013;53(10 Pt 2):2449–58.PubMedGoogle Scholar
  93. 93.
    Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080–99.PubMedGoogle Scholar
  94. 94.
    Chambers RW, Foley HT, Schmidt PJ. Transmission of syphilis by fresh blood components. Transfusion. 1969;9(1):32–4.PubMedGoogle Scholar
  95. 95.
    Kaur G, Kaur P. Syphilis testing in blood donors: an update. Blood Transfus. 2015;13(2):197–204.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Center for Biologics Evaluation & Research V, Blood and biologics fatalities reported to FDA following blood collection and rransfusion: annual summary for fiscal year 2013. 2014; http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm391574.htm. Accessed 12/05/2014, 2014.
  97. 97.
    Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127(4):496–502.PubMedGoogle Scholar
  98. 98.
    Bacterial Detection Testing by Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. US food and drug administration. n.d. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM425952.pdf.
  99. 99.
    Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med. 2016;375(23):2236–45.PubMedGoogle Scholar
  100. 100.
    Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011;155(8):509–19.PubMedGoogle Scholar
  101. 101.
    Linden JV, Prusinski MA, Crowder LA, et al. Transfusion-transmitted and community-acquired babesiosis in New York, 2004 to 2015. Transfusion. 2018;58(3):660–8.PubMedGoogle Scholar
  102. 102.
    Prevention CfDCa. Malaria transmission in the United States. 2015.; https://www.cdc.gov/malaria/about/us_transmission.html. Accessed 1 Mar 2017, 2017.
  103. 103.
    Andreoletti O, Litaise C, Simmons H, et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog. 2012;8(6):e1002782.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Mastrianni JA. The genetics of prion diseases. Genet Med. 2010;12(4):187–95.PubMedGoogle Scholar
  105. 105.
    Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol. 2009;144(1):14–23.PubMedGoogle Scholar
  106. 106.
    Crowder LA, Schonberger LB, Dodd RY, Steele WR. Creutzfeldt-Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk. Transfusion. 2017;57(8):1875–8.PubMedGoogle Scholar
  107. 107.
    van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426–33.PubMedGoogle Scholar
  108. 108.
    McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104(5):1534–41.PubMedGoogle Scholar
  109. 109.
    Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 2005;45(9):1443–52.PubMedGoogle Scholar
  110. 110.
    Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209–17.PubMedGoogle Scholar
  111. 111.
    Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153(3):393–401.PubMedGoogle Scholar
  112. 112.
    Rebulla P, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion. 2017;57(5):1171–83.  https://doi.org/10.1111/trf.14042. Epub 2017.CrossRefPubMedGoogle Scholar
  113. 113.
    van der Meer PF, et al. Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: a randomized controlled trial. Blood. 2018;132(2):223–31.  https://doi.org/10.1182/blood-2018-02-831289. Epub 2018.CrossRefPubMedGoogle Scholar
  114. 114.
    Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang. 2011;100(2):169–78.PubMedGoogle Scholar
  115. 115.
    Wiersum-Osselton JC, et al. Quality validation of data in national haemovigilance systems in Europe: report of a survey on current state of practice. Vox Sang. 2013;104(3):214–7.  https://doi.org/10.1111/j.1423-0410.2012.01659.x. Epub 2012.CrossRefPubMedGoogle Scholar
  116. 116.
    Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006;20(4):273–82.PubMedGoogle Scholar
  117. 117.
    Leach Bennett J, Blajchman MA, Delage G, Fearon M, Devine D. Proceedings of a consensus conference: risk-based decision making for blood safety. Transfus Med Rev. 2011;25(4):267–92.PubMedGoogle Scholar
  118. 118.
    Stein J, Besley J, Brook C, et al. Risk-based decision-making for blood safety: preliminary report of a consensus conference. Vox Sang. 2011;101(4):277–81.PubMedGoogle Scholar
  119. 119.
    Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev. 2009;23(1):1–12.PubMedGoogle Scholar
  120. 120.
    Kacker S, Frick KD, Tobian AA. The costs of transfusion: economic evaluations in transfusion medicine, part 1. Transfusion. 2013;53(7):1383–5.PubMedGoogle Scholar
  121. 121.
    Kacker S, Frick KD, Tobian AA. Establishing a framework: economic evaluations in transfusion medicine, part 2. Transfusion. 2013;53(8):1634–6.PubMedGoogle Scholar
  122. 122.
    Kacker P, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion. 2013;53(9):1885–7.  https://doi.org/10.1111/trf.12186. Epub 2013.CrossRefPubMedGoogle Scholar
  123. 123.
    Kacker S, et al. Data and interpretation: economic evaluations in transfusion medicine, Part 4. Transfusion. 2013;53(10):2130–3.  https://doi.org/10.1111/trf.12185. Epub 2013.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Emily K. Storch
    • 1
  • Brian S. Custer
    • 2
  • Jay E. Menitove
    • 3
  • Paul D. Mintz
    • 4
    Email author
  1. 1.Food and Drug AdministrationBethesdaUSA
  2. 2.UCSF Department of Laboratory MedicineBlood Systems Research InstituteSan FranciscoUSA
  3. 3.Department of Pathology and Laboratory MedicineUniversity of Kansas Medical CenterKansas CityUSA
  4. 4.Verax Biomedical IncorporatedCharlottesvilleUSA

Personalised recommendations